Dr. VG Somani, Drug Controller General of India (DCGI), claimed that India is on track to become a “global hub for medicines,” claiming that there has been a fourfold increase in applications for investigational new drugs in the country.
“We are getting the applications of the investigational new drugs. Earlier, there used to be hardly 5-10 applications. At present, there are 23 applications in the pipeline for the investigational new drug and this is a great achievement of our country,” Somani said, speaking at the Indian Drug Manufacturers’ Association (IDMA) Annual Conclave.
He believes that “Made in India” drugs will make a difference and spread throughout the world in the coming years. The DCGI official also explained how drug controllers work while making vaccine and drug decisions.
“We have been in regular contact with the WHO and all global regulators via the ICMR, ICH platform, and so on. There are various platforms for vaccine and drug approval, including trials. That is exactly what we did with remdesivir. There is no single decision-making platform,” he added. He went on to say that India has been designated as a “world pharmacy,” and that “we want to become the well-managed pharmacy of the entire world so that our potential can be recognised.”